# Waters

# THE ANALYSIS OF TOTAL HOMOCYSTEINE IN PLASMA USING A QUATTRO MICRO TANDEM MASS SPECTROMETER

Scott Gillingwater<sup>1</sup>, Donald Cooper<sup>1</sup>, Michael Morris<sup>1</sup>, Brian Keevil<sup>2</sup> and Stephen McCann<sup>2</sup> <sup>1</sup> Clinical Applications Group, Waters Corporation, Manchester, UK <sup>2</sup> Department of Clinical Chemistry, Wythenshawe Hospital, Wythenshawe, Manchester

### Introduction

Total homocysteine (tHcy) is currently regarded as a risk factor for cardiovascular disease<sup>1</sup>. This increased interest has lead to a multitude of studies requiring the determination of total homocysteine in conjunction with other factors. The introduction of mass spectrometry now allows a single sample to be analysed for a large number of analytes.

There are various methods for measuring tHcy<sup>2</sup>, including HPLC, enzyme immunoassay (EIA) GC-MS and LC-MS/MS. A recent review<sup>3</sup> suggests that GC-MS should be considered as the reference method. A comparison of GC-MS with other laboratory methods drew the conclusion that the methods were not interchangeable and reference material was urgently required<sup>4</sup>.

The most recent method for measuring homocysteine uses a deuterium-labelled internal standard and tandem mass spectrometry<sup>5</sup>. This development requires no derivatisation and therefore leads to an increase in sample throughput<sup>3</sup> compared to existing techniques. We have developed an LC-MS/MS method that requires minimal sample volume, no centrifugation or transfers and therefore allows the possibility of automated sample preparation together with high throughput capability.

## Methodology

A Quattro micro tandem benchtop mass spectrometer fitted with a **Z** SPRAY ion source was used for all analyses. The instrument was operated in electrospray positive ionisation mode and was coupled to a Waters 2790 Alliance HT HPLC system. All aspects of system operation and data acquisition were controlled using MassLynx NT v3.5 software.

Achieving maximum sensitivity for homocysteine can be performed by measuring product ions from the fragmentation of the protonated molecule  $[M+H]^+$ . A solution of homocysteine (10 pmol/µL) was infused into the mass spectrometer and the cone voltage optimised to maximise the intensity of the  $[M+H]^+$  precursor (parent) ion (m/z 136). The collision energy was then adjusted to optimise the signal for the most abundant product ion (m/z 90), using argon as the collision gas at a pressure  $5.0 \times 10^{-3}$  mbar. The product ion spectrum of homocysteine is shown in Figure 1. The process was

repeated for the  $d_4$ -homocysteine analogue, which was used as an internal standard for quantification and to correct for losses during sample processing.



Figure 1. Product ion spectrum of Homocysteine

Plasma (10  $\mu$ L) was aliquoted into a 96 well plate and d8-homocystine, 10 $\mu$ M, (10 $\mu$ L) added and mixed for 1 minute. Dithiothreitol (DTT) 500mM (20  $\mu$ L) was added and mixed for 10 minutes at room temperature.

Finally, water/0.1% formic acid/0.025% trifluoroacetic acid (100  $\mu L)$  was added as a diluent and mixed for 1 minute. The resultant solution was then sampled (4  $\mu L)$  directly from the microtitre well.

The method uses an isocratic elution using a Waters Symmetry C8 column (2.1 x 100 mm, 3.5  $\mu$ m) with aqueous 30% methanol /0.1% formic acid, at 250  $\mu$ L/min. The cycle time (injection-to-injection) is ~2 minutes.

The MRM chromatograms for homocysteine and  $\rm d_{4^-}$  homocysteine are shown in Figure 2.



Figure 2. MRM chromatograms of  $d_4$ -Homocysteine (A) and Homocysteine (B) at a concentration of (10 mM) using the appropriate transition(s).





Plasma containing endogenous Hcy was spiked with a range of known Hcy concentrations (0 5, 10, 15, 25 and 50 µmol/L). The slope and positive intercept, calculated in QuanLynx, are used to calculate the endogenous value (7.96 µmol/L), as shown in Figure 3. The total homocysteine corrected for endogenous content is shown in Figure 4.

Homocysteine	15	15	136 > 90	
d₄-Homocvsteine	15	15	140 > 94	





Figure 3. Calibration curve for the spiked addition of Hcy in Plasma



Figure 4. Corrected calibration curve for tHcy in Plasma

The performance characteristics of the assay were examined using two samples with homocysteine concentrations of 14.6 and 37.7  $\mu$ M. Inter-assay results gave CV's of 5% and 8%, respectively (n=5) and the intra-assay (n=10) CV's for both samples was <2%.

Validation of the method was performed using patient samples (n=50) kindly provided by Wythenshawe Hospital, Manchester, which were analysed using both LC-MS/MS and an Abbot TDx Total Homocysteine kit. The LC-MS/MS method showed excellent correlation (r2 = 0.9149) and slight positive bias (0.44) towards to LC-MS/MS method as shown in Figure 5.



Figure 5. tHcy comparison using LC-MS/MS and an Abbot TDx kit Conclusions

This method has been shown to be rapid, precise and accurate for the measurement of total homocysteine.

The simplicity of the assay makes it ideal both for non-specialised staff and routine high throughput.

#### References

- 1 Boushey CJ. Beresford SA. Omenn GS. Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am. Med. Assoc. 274 (1995) 1049-1057
- 2. Pfeiffer CM. Huff DL. Smith SJ. Miller DT. Gunter EW. Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Clin. Chem. 45 (1999) 1261-1268
- 3. Rasmussen K. Moller J. Total homocysteine measurement in clinical practice. Ann. Clin. Biochem. 37 (2000) 627-648
- Ubbink JB. Delport R. Riezler R. Vermaak WJ. Comparison of three different 4. plasma homocysteine assays with gas chromatography-mass spectrometry. Clin. Chem. 45 (1999) 670-675
- 5 Magera MJ. Lacey JM. Casetta B. Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin. Chem. 45 (1999) 1517-1522

The experiments described in this Application Brief are intended for research purposes only. No use of the Quattro LC as a diagnostic medical device is implied or should be inferred. CAUTION: FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES IN THE UNITED STATES

Micromass Limited (Manchester, UK) and its subsidiary Micromass Inc., (Beverly, MA) DO NOT OFFER FOR SALE OR SUPPORT Quattro LC/NeoLynx TECHNOLOGY FOR U.S.A. NON-RESEARCH USES. The Quattro LC / NeoLynx product is not currently approved by the FDA for use in the United States for clinical diagnostic procedures or for investigational use with or without confirmation of di another medically established diagnostic product or procedure.

Waters and Micromass are registered trademarks of Waters Corporation.

Quattro micro and  $\mathbf{Z}$  SPRAY are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2002 Waters Corporation, (WAB34) Made in the United Kingdom. For research use only. Not for use in diagnostic procedures.

to speak with a waters mass spectrometry specialist, call your local waters ms office: USA 978 524.8200, Belgium 02-2534550, Canada 514 694-1200, Denmark 4657 4101, Europe +31 (0) 36-540 6000, Finland 02 284 56 11, France 0800-907016, Germany 0800-1817249, Italy 02 2159 1415, Netherlands 036-540 6160, Nordic +46 (0) 8 555 115 10, Spain 93 440 71 30, Sweden 08 555 115 10, Switzerland +41 62 88 92 030, UK 0161 435 4125, all other countries: + 44 (0) 161 435 4100